SIMVASTATIN-DRLA is indicated as an adjunct to diet for treatment of hypercholesterolaemia. Prior to initiating therapy with SIMVASTATIN-DRLA, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. SIMVASTATIN-DRLA is indicated in patients at high risk of CHD (with or without hypercholesterolaemia), including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing CHD to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. These effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking. SIMVASTATIN-DRLA is indicated as an adjunct to diet in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heterozygous familial hypercholesterolaemia (HeFH). Prior to initiating therapy with SIMVASTATIN-DRLA, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.
How to take it
The way to take this medicine is: Oral.
This medicine is taken by mouth.
Store below 25 degrees Celsius
Shelf lifetime is 18 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
brown coloured, round, biconvex, film coated tablets debossed 'RDY' on one side and '200' on the other side
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
SIMVASTATIN-DRLA is indicated as an adjunct to diet for treatment of hypercholesterolaemia. Prior to initiating therapy with SIMVASTATIN-DRLA, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. SIMVASTATIN-DRLA is indicated in patients at high risk of CHD (with or without hypercholesterolaemia), including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing CHD to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. These effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking. SIMVASTATIN-DRLA is indicated as an adjunct to diet in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heterozygous familial hypercholesterolaemia (HeFH). Prior to initiating therapy with SIMVASTATIN-DRLA, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.
How to take it
The way to take this medicine is: Oral.
This medicine is taken by mouth.
Store below 25 degrees Celsius
Shelf lifetime is 18 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
brown coloured, oval shaped, biconvex, film coated tablets debossed 'RDY' on one side and '268' on the other side
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
SIMVASTATIN-DRLA is indicated as an adjunct to diet for treatment of hypercholesterolaemia. Prior to initiating therapy with SIMVASTATIN-DRLA, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. SIMVASTATIN-DRLA is indicated in patients at high risk of CHD (with or without hypercholesterolaemia), including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing CHD to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. These effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking. SIMVASTATIN-DRLA is indicated as an adjunct to diet in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heterozygous familial hypercholesterolaemia (HeFH). Prior to initiating therapy with SIMVASTATIN-DRLA, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.
How to take it
The way to take this medicine is: Oral.
This medicine is taken by mouth.
Store below 25 degrees Celsius
Shelf lifetime is 18 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
brown coloured, round, biconvex, film coated tablets debossed 'RDY' on one side and '198' on the other side
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
SIMVASTATIN-DRLA is indicated as an adjunct to diet for treatment of hypercholesterolaemia. Prior to initiating therapy with SIMVASTATIN-DRLA, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. SIMVASTATIN-DRLA is indicated in patients at high risk of CHD (with or without hypercholesterolaemia), including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing CHD to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. These effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking. SIMVASTATIN-DRLA is indicated as an adjunct to diet in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heterozygous familial hypercholesterolaemia (HeFH). Prior to initiating therapy with SIMVASTATIN-DRLA, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.
How to take it
The way to take this medicine is: Oral.
This medicine is taken by mouth.
Store below 25 degrees Celsius
Shelf lifetime is 18 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
brown coloured, round, biconvex, film coated tablets debossed 'RDY' on one side and '199' on the other side
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
